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Abstract
We have used a systematic methodology to tailor the in-vitro drug release profiles
for a system of PLGA/PLA nanoparticles encapsulating a hydrophobic drug, haloperidol.
We applied our previously developed sonication and homogenization methods to produce
haloperidol-loaded PLGA/PLA nanoparticles with 200-1000 nm diameters and 0.2-2.5 %
drug content. The three important properties affecting release behavior were identified as:
polymer hydrophobicity, particle size and particle coating. Increasing the polymer
hydrophobicity reduces the initial burst and extends the period of release. Increasing the
particle size reduces the initial burst and increases the rate of release. It was also shown
that coating the particles with chitosan significantly reduces the initial burst without
affecting other parts of the release profile. Various combinations of the above three
properties were used to achieve in-vitro release of drug over a period of 8 days, 25 days,
and >40 days, with initial burst < 25% and a steady release rate over the entire period of
release. Polymer molecular weight and particle drug content were inconsequential for
drug release in this system. Experimental in-vitro drug release data were fitted with
available mathematical models in literature to establish that the mechanism of drug
release is predominantly diffusion controlled. The average value of drug diffusivities for
PLGA and PLA nanoparticles was calculated and its variation with particle size was
established.
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1. Introduction
Time-controlled drug delivery can be achieved through polymeric drug delivery
systems, using the widely accepted biodegradable polymer PLGA (Bala et al., 2004).
Two promising candidates among the PLGA based polymeric drug delivery systems
include microparticles and nanoparticles containing the active pharmaceutical agent
encapsulated in PLGA matrix. PLGA based microparticles have been studied extensively
and several products are available on market (Woo et al., 2001; Dong et al., 2003).
However, for site-specific controlled drug delivery, nanoparticles offer additional
advantages due to their submicron size, which makes extravasation possible and
occlusion of terminal blood vessels unlikely (Barratt, 2003).
While the drug release behavior has been studied for PLGA based microparticles
and nanoparticles encapsulating various hydrophobic drugs (Avgoustakis, 2004), there
have been few attempts to develop a systematic methodology to understand and modulate
the drug release profile. Previous attempts to tailor the release profiles include that of
Ravivarapu et al. (2000), who utilized polymer and microparticle blending to achieve
desired release profiles for a system of peptide-loaded PLGA microparticles. They
blended PLGA polymers of different molecular weights to make microparticles and also
produced peptide-loaded microparticles from different molecular weight PLGA. This is a
good strategy to control the drug release from a microparticulate system since the drug
release is affected by diffusion as well as polymer degradation and the latter is strongly
affected by polymer molecular weight. However, the release profile of our nanoparticles
is not expected to be a strong function of polymer molecular weight and we need to
develop other strategies to tailor the release profiles. The primary objective of our
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research is to achieve drug release profiles with desired characteristics in terms of time
period and rate of drug release. This is realized by first interpreting the effect of particle
and polymer properties on drug release in terms of the scientific principles involved in
the process of drug release and then employing these effects to tailor the release profiles.
The in-vitro release of a hydrophobic drug from a biodegradable nanoparticulate
system is affected by the properties of polymer and particles (Bodmer et al., 1992; Park,
1994; Chorny et al., 2002; Duan et al., 2006). Controlling the release is tantamount to
controlling the properties affecting release, including particle size, size distribution, drug
content, polymer properties, and surface properties. The mechanism of drug release plays
a vital role in determining how the above properties influence the in-vitro release
behavior. The mechanism varies from diffusion-controlled to polymer erosion controlled
release and is usually some combination of the two. For our system of haloperidol-loaded
PLGA/PLA nanoparticles, we have previously hypothesized the mechanism to be
predominantly diffusion controlled for particles with bimodal size populations (Budhian
et al., 2005). Here, another objective is to verify this hypothesis by collecting in-vitro
release data from unimodal PLGA/PLA nanoparticles of various sizes and fitting it to
mathematical models in literature based on Fick’s second law of diffusion (Ritger and
Peppas, 1987 I, II; Siepmann et al., 2005). Once we establish the mechanism to be
diffusion controlled, we can then understand the drug release behavior by employing
scientific principles pertaining to diffusion of drug molecules through PLGA/PLA
matrices.
The general release profile from nanoparticles has four important components:
initial burst, induction period, slow release period, and final release period. The initial
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burst is caused mainly due to rapid water intake by the particle surface region, which
results in swelling of chains close to the surface and drastically increases the diffusion of
the drug molecules dispersed in this region. Initial burst could be minimized by
exercising the following effects: (i) reduce the amount and/or rate of water intake, (ii)
increase diffusional resistance to the drug by providing longer diffusion pathways to the
drug molecules, and/or (iii) reduce the amount of drug in the surface region. The initial
burst is followed by the induction period. Here the particle is hydrated by the release
medium and the drug is released in a continuous fashion at a fast rate. The release
medium diffuses into the particle core forming a diffusion front that travels from surface
to the core. We can control the induction period by (i) controlling the rate at which the
diffusion front moves from the surface to the core and (ii) controlling the length of the
diffusion pathway for the drug molecules. It was determined that the above-mentioned
effects on initial burst and induction period were most significantly realized by
manipulating the polymer hydrophobicity, the coating on the particle surface, and/or
particle size.

2. Materials and Methods
2.1 Materials
Poly (D,L-lactic-co-glycolic acid) (PLGA) 50:50 DL (inherent viscosity, 0.37
dL/g), 50:50 DL (0.44 dL/g), 75:25 (0.55 dL/g), 100:0 (0.68 dL/g) were purchased from
Alkermes, USA.

Polyvinyl alcohol (PVA) (MW, 25,000, 88% hydrolyzed) was

purchased from Polysciences Inc., USA. Haloperidol, phosphate buffered saline (PBS),
ammonium acetate, 1-Piperazineethane sulfonic acid, 4-(2-hydroxyethyl)-monosodium
5

salt (HEPES), gelatin, and chitosan were purchased from Sigma, USA. Acetonitrile,
dichloromethane (DCM) and acetone were purchased from Fisher scientific. All the
solvents were HPLC grade.

2.2 Nanoparticle Preparation
Nanoparticles were prepared by using two methods: 1.) Emulsification by
homogenization-solvent evaporation, and 2.) Emulsification by sonication-solvent
evaporation. Henceforth, these methods will be referred as simply homogenization and
sonication. Both methods involve preparation of an organic phase consisting of polymer
(PLA or PLGA) and drug (haloperidol) dissolved in organic solvent (DCM). The organic
phase is added to an aqueous phase containing a surfactant (PVA) to form an emulsion.
This emulsion is broken down into nanodroplets by applying external energy and these
nanodroplets form nanoparticles upon solvent evaporation. Details of both methods have
been discussed in our earlier publications (Budhian et al., 2005, 2006,).
Once the colloidal suspension of nanoparticles is prepared using either of the
above methods, the free drug is removed by using our free drug extraction method to
obtain the final nanoparticulate suspension (Budhian et al., 2005). Some particles were
coated with chitosan, L101 or gelatin. The coating was done by first freeze drying a batch
of particles and then carefully spreading a drop of 1 % solution of chitosan, L101, or
gelatin on the surface of particles and then mixing it to ensure that the particles are coated
evenly. In the case of chitosan, the coating protocol was later modified to be an in situ
coating method where chitosan was added to the nanoparticulate suspension after free
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drug removal to form a 1 % chitosan solution. This promotes a uniform chitosan coating
on the particle surface and prevents agglomeration of the particles.
Unless otherwise mentioned, all the experiments are conducted by varying one
parameter while keeping all the other processing parameters at the standard condition: 10
mg/ml of PLGA 50:50, 3.5A, MW 51 kD and 0.5 mg/ml of haloperidol in DCM as the
organic phase and 50 ml of 1 % PVA solution as the aqueous phase. The aqueous to
organic ratio and the surfactant to PLGA ratio is 10:1 and polymer to drug ratio is 20:1.
Solvent volume is 5 ml. Sonication is carried out at a power of 7 for 7 minutes.

2.3 Nanoparticle Characterization
Nanoparticles were characterized for size, size distribution, and drug content as
detailed in our earlier publication (Budhian et al., 2005). The size and size distribution
were measured by laser dynamic light scattering. The haloperidol content was measured
using HPLC. Briefly, the nanoparticle suspension (coated or uncoated particles) was
completely dissolved in the mobile phase of HPLC and injected into the machine as
detailed in our earlier publication. (Budhian et al., 2005). Drug content was calculated as
the ratio of the mass of drug inside the nanoparticles to the total initial mass amount of
the polymer.

2.4 In Vitro Release Studies
The in vitro release study of the haloperidol-loaded PLGA nanoparticles was
carried out in triplicate in stirred dissolution cells at 37.4°C by suspending 1-2 ml of the
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nanoparticulate suspension in a large quantity (100-200 ml) of pH 7.4 PBS solution such
that the total amount of haloperidol inside the suspended nanoparticles is less than 10%
of its solubility limit in PBS buffer. This ensures the correct in vitro conditions to study
the release behavior of a hydrophobic drug (Chorny et al., 2002). One ml aliquots were
taken out of the dissolution cells at pre-determined time intervals, replaced by fresh PBS
buffer and analyzed for released haloperidol by HPLC.

The cumulative % release

profiles were obtained by taking the ratio of the amount of haloperidol released to the
total drug content in the same volume of sample.

3. Results and Discussion
We now present the isolated effects of L:G ratio, drug content, surface coating
and particle size on the kinetics of drug release. For all the figures, each point represents
the mean value from one batch of nanoparticles from multiple dissolution cells and error
bars indicate the standard deviation within a batch. Error bars are omitted when the error
is <10 % of the mean. We used our method of sonication to produce 220 nm particles
with very narrow size distribution. We were also able to produce uniformly sized
particles by our homogenization method for various polymer types and drug contents by
selecting the materials and/or controlling the processing conditions as described in our
previous publication (Budhian et al., 2006). The polydispersity index of the particle size
ranges from 0 to 0.3, where 0.3 refers to the most polydisperse population. The
polydispersity indexes of these haloperidol-PLGA nanoparticles, particularly those
prepared by sonication, are low and show little variability between different batches of
particles prepared under various conditions. Unless otherwise mentioned, the
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polydispersity indexes of unimodal particles prepared by sonication are 0.05-0.07, while
those from homogenization are 0.10-0.14.

3.1 Effect of L:G Ratio

Figure 1a shows the cumulative % haloperidol released as a function of time from
three batches of nanoparticles made from PLA using the sonication method. The size of
particles from each batch is 220 nm and the drug content is 1.7 %.
Figure 1a demonstrates our capacity to produce a system of small nanoparticles
(~220 nm) that releases haloperidol consistently with an extraordinary reproducibility
across different batches. The drug release profile from nanoparticles can be divided into
four zones: (i) Initial burst period, during which the surface drug is dumped into the
release medium; here it is taken as one day (ii) Induction period, during which the drug is
released at a gradually-decreasing fast rate (iii) Slow release period, during which the
drug is released at a steady slow rate (iv) Final release period (not shown), during which
the particle disintegrates to release the remaining drug at a fast rate.
Figure 1b shows the haloperidol release profiles from nanoparticles made from
PLGA 50:50 and PLA. The size of particles is 220 nm and the drug content is 1.3 % for
PLGA particles and 1.7 % for PLA particles.
The drug release process over a long period of time is expected to be influenced
by the polymer L:G ratio since the process is controlled by the degradation rate of
polymer, which is affected by polymer hydrophobicity. Strong L:G dependence of release
profile has been reported by Bodmeier et al. (1989) for water-soluble drugs (salicylic
acid, caffeine, and quinidine) incorporated in PLGA and PLA films and microspheres and
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by Mu and Feng (2002) for a hydrophobic drug (paclitaxel) incorporated in PLGA
nanoparticles. For both these cases the drug release mechanism was a combination of
drug diffusion and polymer degradation.
However, the drug release mechanism in the haloperidol-PLGA system is
suspected to be predominantly diffusion controlled (Budhian et al., 2005). Hence the
influence of L:G ratio cannot be attributed entirely to slow polymer degradation. During
the drug release process, the drug diffuses through the hydrated polymer matrix into the
aqueous phase. The process of hydration relaxes the polymer chains and enhances the
diffusion of drug molecules. The rate of water uptake (hydration) of polymer particles
increases with the hydrophilicity of polymer. Hence the initial burst is higher for more
hydrophilic (PLGA) particles than less hydrophilic (PLA) particles. The induction period
is also affected by polymer hydrophobicity. Decreasing the hydrophobicity increases the
rate at which the diffusion front (of the release medium) moves from the surface to the
core, which makes more drug available for diffusion in a less time and thus reduces the
induction period.

3.2 Effect of Drug Content
Figures 2(a, b) show the haloperidol release profiles from 220 nm PLA particles
prepared by sonication and having a drug content of 0.66 %, 1.7 % and 2 %. As the drug
content increases, the absolute initial burst increases from 7 to 17 µg/ml. The % release
profile is not significantly affected by change in drug content (Figure 2 b).
The increase in drug content in the particles influences the absolute release
profiles such that both, the cumulative amount of drug released at any time (including
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initial burst) and the induction period increases. The increase in drug content increases
the amount of drug close to the surface as well as the drug in the core of nanoparticles.
The former is responsible for an increased initial burst while the latter causes an increase
during the induction period.
For the cumulative % haloperidol release profiles, the increase in the drug
released is offset by the increase in the total amount of drug contained in the particles.
The final effect on release profile is determined by the larger of the above mentioned
ratios. The drug released during initial burst is predominantly the drug located close to
the surface. For our system, the slight decrease in initial burst on increasing the drug
content probably happens due to uneven drug distribution inside the particles. On
increasing the drug content, the marginal increase in this surface-associated drug is less
as compared to the marginal increase in the total drug. Hence, the initial burst given as a
% haloperidol decreases on increasing the drug content. Similar trend has been
previously reported (Avgoustakis et al., 2002; Ruan and Feng, 2003) for various
nanoparticulate and microparticulate systems. The opposite trend has also been reported
(Allemann et al., 1993; Huang et al., 1999; Chorny et al., 2002) for some PLGA
microparticle and nanoparticle systems with different drugs. The discrepancy occurs
probably due to excess drug at the nanoparticle surface in the latter case that is
immediately released.

3.3 Effect of Coating the Particles
Figure 3a shows the haloperidol release profile from 220 nm PLA particles:
uncoated or coated with gelatin, chitosan, or L101, prepared by sonication. Particles have
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a drug content of 1.3 %. The % haloperidol released at the end of day 1 (initial burst)
from uncoated particles is 46 %, while that from particles coated with gelatin, L101 and
chitosan is 30 %, 20 % and 17 %, respectively. Figure 3b shows the haloperidol release
profile from 220 nm particles coated with chitosan and prepared from PLGA 50:50 and
PLA using the method of sonication. The initial burst is ~20 % for PLA particles and
~43 % for PLGA particles.
All the particles are physically coated with various coating agents and the coating
process is solely due to physical adsorption or electrostatic interactions between the
polymer chains and the coating material. On coating the particles with a thin layer of
different substances (chitosan, L101, gelatin) the drug molecules have to pass through an
additional layer of diffusional resistance created by the coating substance. This slows
down the release process and, in particular, reduces the initial burst. A reduction in initial
burst for a hydrophobic drug (lidocaine) encapsulated in PLGA films or microspheres
coated with gelatin or chitosan has been reported (Huang et al., 1999; Chiou et al., 2001).
Similarly, a reduction in initial burst for coated PLGA microspheres containing a
hydrophilic drug (bovine serum albumin) has been reported (Park et al., 1992). In all
these case, the coating was achieved by simply dipping the polymer films or
microparticles in the coating solution, which is impractical for a nanoparticulate system
due the increased tendency of agglomeration post-coating. We overcome this issue of
particle agglomeration by using the in situ coating method, which is better suited for
particles of such small size.
Chitosan was chosen as the coating material for further studies since it reduces the
initial burst most effectively. Chitosan is a polysaccharide having a number of –OH and –
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NH groups that provide opportunities of intermolecular hydrogen bonding with PLGA
and PVA. Chitosan forms an entangled network layer on the particle surface and restricts
the infiltration and diffusion of water. Further, the solubility of chitosan is a function of
pH and at a pH of 7.4 it is practically insoluble in water, which further reduces the rate of
water absorption by the particles. The diffusion of drug molecules from nanoparticles
surface to the surrounding medium is limited by the entanglements caused by chitosan
layer, which reduces the initial burst. The burst is also reduced because now the surface
region contains less drug since the coated chitosan layer is devoid of drug. Comparison of
Figure 3b with Figure 1b clearly shows the reduction in burst release achieved by coating
220 nm PLGA or PLA particles with chitosan. The batch-to-batch variation for PLA
particles (Figure 3b) might be attributed to different coating methods (coating of freezedried particles vs. in situ coating of nanosuspension). The in-situ method was used for
further studies. Coating the particles with chitosan can significantly reduce the initial
burst in the release profiles obtained from various haloperidol-loaded nanoparticles.

3.4 Effect of Particle Size
Figure 4a compares the haloperidol release profiles from PLA particles with 1.8
% drug content having different diameters. The 220 nm particles were prepared using
sonication at standard conditions, while the 450 nm and 1300 nm particles were prepared
using homogenization at different speeds. As the size increases, the initial burst decreases
and the induction period increases.
The burst is reduced because on increasing the size, the total surface area of a
constant weight of particles decreases. Increasing the size of particles increases the length
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of diffusion pathways for the drug molecules. For the same amount of drug inside the
particles, increasing the length of diffusion pathways exercises two opposing effects on
the induction period. The induction period increases because the drug molecules have to
traverse a longer distance within the polymer matrix to reach the surface. However, the
products of polymer degradation also have to travel a longer distance before they can
dissolve in the release medium. The trapped products increase the local pH within the
polymer matrix, which accelerates the polymer degradation due to autocatalysis
(Siepmann et al., 2005). This accelerates the rate of loss of molecular weight within the
matrix leading to faster drug diffusion. This has an effect of reducing the induction
period. The final value of induction period depends on the dominating mechanism. For
our small sized particles (<1000 nm), autocatalysis is insignificant and the overall impact
of increasing the diffusion pathways (by increasing the particle diameter) is an increase in
induction period and the induction amount.

3.5 Tailored Release Profiles
Figure 5 shows the haloperidol release profiles for two batches of chitosan coated
particles prepared by using homogenization and made from PLGA 75:25, PLGA 50:50
and PLA. These results demonstrate our capacity to tailor the in-vitro drug release
profiles to achieve specific objectives in terms of drug release period and the release rate.
We would ideally want to have a zero initial burst and a steady and constant rate of drug
release over a desired period of release.
As we have demonstrated above, the release profile is mainly a function of
polymer hydrophobicity, particle size, particle surface, and specific interactions in the
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system. However, each parameter exercises multiple effects on each part of the release
profile and getting a desired release profile involves identifying the dominant influences
and manipulating multiple parameters simultaneously to reach the desired objective. We
can adjust the parameters so that the entire drug is released in the induction period itself
and the usual triphasic profile is reduced to a single continuous profile. The next step is to
reduce the initial burst so as to maximize the induction amount. Finally, the induction
period is adjusted in accordance with the given objectives. For example, if the objective
is to design a release system for medium release times (~7-8 days), then we can take the
following steps: (i) increase the polymer hydrophilicity to reduce the triphasic profile into
a continuous profile, (ii) coat the particles with appropriate agent to reduce the initial
burst and maximize the induction amount without significantly affecting the slope of the
release profile, and (iii) adjust the period of release by increasing/decreasing the effective
drug diffusivity out of the polymer matrix by changing the size of the particles and/or
utilizing specific interactions in the system. For example, for our haloperidol-PLGA
system, the objective of achieving continuous release for medium release times can be
achieved with the following multifaceted approach. (i) Given that the release is strongly
affected by the haloperidol-PLGA end group interaction, we chose the polymers having
acid end group so as to reduce the burst and prolong the induction period for small
(<1000 nm) particles. Since PLA polymer is highly hydrophobic and it gives a typical
triphasic profile that extends for longer periods (>35 days), we decide to use the
hydrophilic acid end group PLGA polymers. (ii) After selecting the end group, we fix the
size of the particles to the smallest possible size (~220 nm). (iii) Next, we realize that the
induction amount can be substantially increased by reducing the high initial burst
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associated with small sized (<1000 nm) PLGA 50:50 nanoparticles. So we coat the
particles with chitosan to reduce the initial burst. (iv) Finally, we increase the induction
period to the desired value (~7-8 days) by increasing the size as well as hydrophobicity of
the polymer. The increase in hydrophobicity further reduces burst and increases the
induction period at the cost of reducing the induction-release-slope. This is overcome by
increasing the size of particles, which reduces burst, increases the induction period and
also increases the induction-release-slope and compensates for the decrease in slope
caused by polymer hydrophobicity. After a careful manipulation of hydrophobicity and
size, we find that chitosan coated PLGA 75:25 particles of diameter 400 nm can achieve
the desired objective (Figure 5a). Note that we can also achieve this objective by utilizing
other combinations of polymer characteristics and particle properties if there are other
constraints on size, hydrophobicity or any other property of the system. This releaseprofile-tailoring scheme is based on general scientific principles governing the release of
any hydrophobic drug from a biodegradable polymer system and can be applied to a
model hydrophobic-drug-polymer system after taking into account the specific
interactions/properties present in the system.

4. Mathematical Modeling of Drug Release
The aim of this section is to utilize the already existing mathematical models in
literature to verify our earlier hypothesis that the release from our nanoparticulate system
is predominantly diffusion controlled (Budhian et al., 2005) and to understand how the
diffusion mechanism and the corresponding drug diffusivities are affected by the size and
hydrophobicity of the particles.
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4.1 Verification of diffusion hypothesis
The drug release from polymeric micro/nano-particulate systems is usually
considered as a combination of Fickian (diffusion) and non-Fickian movement of drug
molecules through polymer chains (Kosmidis et al., 2003). Ritger and Peppas (1987 I, II)
gave the semi-empirical equation to describe the release of solute when the prevailing
mechanism is a combination of Fickian and non-Fickian mechanisms:

Mt
= kt n + α
M∞

(1)

where M t is the drug released at time t , M ∞ is the quantity of drug released at infinite
time, k is the kinetic constant, n is an exponent, and α represents the drug released at
zero time and accounts for the initial burst (Huang and Brazel, 2001). The value of n is
related to both the geometrical shape of the formulation and the release mechanism. For
drug release from spherical particles, the value of n is equal to 0.43 for pure Fickian and
0.85 for pure non-Fickian mechanisms.
We fit our experimental release data to theoretical release profiles given by
Equation 1 and determine the value of the exponent n so as to test our hypothesis. Figure
4b shows the theoretical fit to experimental release data for haloperidol loaded PLA
nanoparticles of various diameters. The symbols indicate experimental results and solid
lines indicate the best fit as described by Equation 1. The values of different parameters
corresponding to the best-fit lines are given below.
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Mt
= 0.053 t 0.433 + 46
M∞

(2)

Mt
= 0.078 t 0.438 + 23
M∞

(3)

Mt
= 0.112 t 0.435 + 4
M∞

(4)

The value of n is ~0.43 for various particle sizes indicating that the drug release is
diffusion controlled. The experimental and theoretical profiles for PLGA 50:50 particles
start deviating at ~10 days (data not shown), after which the release becomes slower than
predicted by the diffusion equation. This deviation of release profiles starts at a much
later time for PLA particles. This deviation suggests that the release mechanism is
diffusion controlled for the initial few days, after which the role of polymer degradation
becomes important in PLGA 50:50 particles. The polymer degradation is faster for PLGA
particles than for PLA particles and hence the deviation from experimental profiles is
observed much earlier for PLGA particles.

4.2 Analysis of drug release by diffusion
Once the mechanism of drug release is established as diffusion controlled, we can
calculate the drug diffusivity using Fick’s second law of diffusion, under the assumptions
of homogenous drug distribution, molecular dispersion of drug in the polymer matrix,
negligible diffusional resistance in the liquid boundary layers, and perfect sink conditions
(Siepmann et al., 2005). Siepmann et al. (2005), have developed a mathematical model to
describe drug release behavior when diffusion is the controlling mechanism of drug

18

release. The model employs Fick’s second law of diffusion to describe drug diffusion
from spherical polymer particles:

⎛ ∂ 2 c 2 ∂c ⎞
∂c
⎟
= D⎜⎜ 2 +
∂t
r ∂r ⎟⎠
⎝ ∂r

(5)

where c denotes the concentration of drug, t represents time, D is the diffusion
coefficient, and r is the radial coordinate. The initial value problem described by
Equation 5 is solved by applying appropriate boundary conditions and using the
simplification that diffusional resistance within the unstirred liquid boundary layers is
negligible compared to the diffusional resistance within the polymeric matrix. The
solution of Equation 5 is as follows:
Mt
6
= 1− 2
M∞
π

⎞
⎛ n 2π 2
1
⎜⎜ − 2 Dt ⎟⎟ + α
exp
∑
2
n =1 n
⎠
⎝ R
∞

(6)

Figure 4c shows the theoretical fit of Equation 6 to our experimental release data
for haloperidol loaded PLA nanoparticles of various diameters. The values of drug
diffusivity corresponding to the best-fit lines are as given in Table 1 for both PLA and
PLGA 50:50. There are two important observations regarding drug diffusivity. First, for
constant size particles, the diffusivity of drug molecules in PLGA 50:50 particles is
approximately 16 times the diffusivity in PLA particles. Second, for a given polymer, the
drug diffusivity increases as the size of particles increases.
The increase in drug diffusivity in degrading PLGA particles as compared to PLA
particles can be understood in terms of established results in literature for degrading
19

PLA/PLGA micro- and nano- particles without any encapsulated drug. For a given
particle size, the diffusivity is a function of polymer molecular weight (Raman et al.,
2005), which varies with time for a degrading polymer system (Belbella et al., 1996). For
very small nanoparticles (~220 nm diameter), the molecular weight of PLA particles
remains constant for about 10 weeks, while the molecular weight of PLGA particles
gradually decreases until they are completely degraded in about 8 weeks (Zweers et al.,
2004). Thus the drug diffusivity in 220 nm PLA particles stays constant with time (in the
range tested), while it increases with time for 220 nm PLGA particles. Hence the average
value of drug diffusivity in 220 nm PLGA particles is higher than in PLA particles.
The increase in drug diffusivity with particle size for haloperidol-PLA
nanoparticulate system in the diameter range 220 – 1300 nm can be mathematically
expressed by plotting the data in Table 1 to a best-fit curve. The corresponding equation
for this best-fit curve thus obtained is:

D[cm 2 / s ] = 1 *10 −16 R[ μm] 2.4648

(7)

The increase in drug diffusivity with particle size for lidocaine-loaded PLGA
microparticles in the diameter range 7 – 60 microns has been previously attributed to
autocatalytic effects with increasing device dimension (Siepmann et al., 2005), the
corresponding equation being, D[cm 2 / s ] = 1.1 * 10 −15 R[ μm]1.887 , where R is the radius of
particles. However, it has also been argued that, in the nanoparticle range, the
autocatalytic effects (in the absence of drug) are absent or perhaps less prominent
(Zweers et al., 2004). This motivates us to use Equation (7) to establish the effect of
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particle size on drug diffusivity in the nanoparticle size range, in the presence of a drug.
Equation (7) establishes that, as the particle size is decreased, the autocatalytic effects
initially do cause a decrease in drug diffusivity, after which their magnitude decreases
and the drug diffusivity plateaus at a particle diameter of ~220 nm, showing the absence
of autocatalytic effects at this particle size for our system.
The value of haloperidol diffusivity in PLA matrix for small sized PLA particles
is of the order of 10-19 - 10-18 cm2/s, which is about two orders of magnitude less than the
diffusivity of some other system of nanoparticles reported in literature, Table 1
(Polakovic et al., 1999; Chorny et al., 2002; Rouzes et al., 2003). The primary reason for
this discrepancy is the strong hydrogen bonding interaction between haloperidol and the
carboxylic acid group of PLA (Budhian et al., 2005). The drug release rate and hence the
apparent diffusivity is reduced due to this strong drug-polymer interaction. Other reasons
for the discrepancy include the difference in polymer molecular weight and the different
assumptions used to solve Fick’s second law. Hence the drug diffusivity in polymer
matrix for a system of haloperidol loaded PLGA/PLA nanoparticles is a complex
function of polymer molecular weight (which changes with time depending on polymer
hydrophobicity) and particle size.

5. Conclusions
Haloperidol-loaded PLGA/PLA particles were produced by sonication or
homogenization and tested for their in vitro release behavior. The effects of various
particle properties including, polymer hydrophobicity, particle drug content and surface
coating, on the release behavior were understood separately. Subsequently, this
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understanding was integrated to achieve desired haloperidol release profiles. The three
most important properties affecting release behavior were identified as: polymer
hydrophobicity, surface coating, and particle size. Polymer hydrophobicity reduces the
initial burst and prolongs the period of release. For example, the initial burst and the %
drug released in 35 days is 46 % and 70 % for 220 nm PLA particles as compared to 70
% and 90 % for 220 nm PLGA particles. Coating the particle surface with chitosan
considerably reduces the initial burst, without significantly affecting the release rate. For
example, the initial burst from 220 nm PLGA particles with 1.3 % drug is reduced from
70 % to 36 % by coating them with chitosan. Increasing the size of the particles reduces
the initial burst and increases the rate of release. For example, increasing the size from
220 nm to 450 nm reduces the initial burst from 48 % to 28 % and results in a steady
release of drug over a 10 day time period as compared to 4 days. We successfully
integrated these three properties to produce nanoparticles having a release profile with
reduced burst and steady release over a desired time period. For example, 400 nm PLGA
75:25 particles, coated with chitosan provide steady release for 8 days with an initial
burst of just 30 %. The predominant mechanism of drug release was confirmed to be
diffusion controlled by the application of mathematical models and the corresponding
drug diffusivities were established to be a function of both polymer hydrophobicity and
particle size. Hence, the release profile from haloperidol loaded PLGA/PLA
nanoparticles can be tailored to achieve desired objectives by selective manipulation of
particle properties. These principles can be applied to a general hydrophobic-drugpolymer system after taking into account the specific interactions involved in the system.
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List of Tables and Figures:

Table 1: Drug diffusivities, D, from the haloperidol-PLGA/PLA nanoparticles in Figure
4c and other PLA-hydrophobic drug systems in literature.

Figure 1: (a) Overall haloperidol release profiles from three batches of PLA
nanoparticles. Each batch has a mean diameter of 220 nm and a drug content of 1.7%. (b)
Haloperidol release profiles from PLA (◇) and PLGA (■, □) particles having a mean
diameter of 220 nm. Drug content is 1.7 % for PLA particles and 1.3 % for PLGA
particles. In this and subsequent figures, each point represents a batch and error bars
indicate the standard deviation of the mean reading within a batch. Error bars are omitted
when the error is within 10 % of the mean reading.

Figure 2: (a) Absolute and (b) normalized haloperidol release profiles from 220 nm PLA
particles having a drug content of 2% (◇), 1.7 % (◆), 0.66 % (▲).

Figure 3: (a) Haloperidol release profiles from 220 nm PLA particles: uncoated (◆), and
coated with gelatin (□), chitosan (◇), or L101 (△). (b) Haloperidol release profiles from
220 m particles coated with chitosan and prepared from PLGA 50:50 (◆) or PLA (■, □).
PLGA and PLA particles have a drug content of 1.3 % and 1.7 %, respectively.

24

Figure 4: Haloperidol release profiles from PLA particles having diameters of 220 nm
(▲), 450 nm (■), and 1300 nm (◆). All particles have ~1.8 % drug content. (b, c)
Theoretical fit to experimental release data shown in (a). Symbols indicate experimental
data and solid lines indicate release profile according to Equation 1, (b), and Equation 6,
(c).

Figure 5: Haloperidol release profiles from chitosan coated (a) 400 nm PLGA 75:25
particles (■, □) having a drug content of 2 % and (b) 900 nm PLGA 50:50 (◆, ◇) and
PLA (■, □) particles having a drug content of 2.4 % and 2.7 %, respectively.

25

References

Allemann, E., Leroux, J.C., Gurny, R., Doelker, E., 1993. In vitro extendedrelease properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by
a salting-out procedure. Pharm. Res., 10, 1732-1737.

Avgoustakis, K., 2004. Pegylated poly(Lactide) and poly(lactide-co-glycolide)
nanoparticles: preparation, properties and possible applications in drug delivery.
Curr. Drug Deliv., 1, 321-333.

Avgoustakis, K., Beletsi, A., Panagi, Z., Klepetsanis, P., Karydas, A.G.,
Ithakissios, D.S., 2002. PLGA-mPEG nanoparticles of cisplatin: in vitro
nanoparticle degradation, in vitro drug release and in vivo drug residence in blood
properties. J. Control. Release., 79, 123-135.

Bala, I., Hariharan, S., Kumar, M.N., 2004. PLGA nanoparticles in drug delivery:
the state of the art. Crit. Rev. Ther. Drug Carr. Sys., 21, 387-482.

.

Barratt, G., 2003. Colloidal drug carriers: achievements and perspectives. Cell.
Mol. Life Sci., 60, 21 - 37.

26

Belbella, A., Vauthier, C., Fessi, H., Devissaguet, J.P., Puisieux, F., 1996. In vitro
degradation of nanospheres from poly(D,L-lactides) of different molecular
weights and polydispersities. Int. J. Pharm., 129, 95-102.

Bodmeier, R., Oh, K.H., Chen, H., 1989. The effect of the addition of low
molecular weight poly(DL-lactide) on drug release from biodegradable poly(DLlactide) drug delivery systems. Int. J. Pharm., 51, 1-8.

Bodmer, D., Kissel, T., Traechslin, E., 1992. Factors influencing the release of
peptides and proteins from biodegradable parenteral depot systems. J. Control.
Release., 21, 129-138.

Budhian, A., Siegel, S.J., Winey, K.I., 2005. Production of haloperidol loaded
PLGA nanoparticles for extended controlled drug release of haloperidol. J.
Microencapsul., 22, 773-785.

.

Budhian, A., 2006. Achieving long-term controlled drug delivery by using
biodegradable polymeric nanoparticles. Ph.D Thesis, Chemical and Biomolecular
Engineering. University of Pennsylvania, Philadelphia.

.

Budhian, A., Siegel, S.J., Winey, K.I., 2007. Haloperidol-loaded PLGA
nanoparticles: systematic study of particle size and drug content. Int. J. Pharm., In
press.

27

Chiou, S.H., Wu, W.T., Huang, Y.Y., Chung, T.W., 2001. Effects of the
characteristics of chitosan on controlling drug release of chitosan coated PLLA
microspheres. J. Microencapsul., 18, 613-625.

.

Chorny, M., Fishbein, I., Danenberg, H.D., Golomb, G., 2002. Lipophilic drug
loaded nanospheres prepared by nanoprecipitation: effect of formulation variables
on size, drug recovery and release kinetics. J. Control. Release., 83, 389-400.

Chorny, M., Fishbein, I., Danenberg, H.D., Golomb, G., 2002. Study of drug
release mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and
external sink methods. J. Control. Release., 83, 401-414.

Dong, H. N., Youna, Y.S., Leea, S.D., Sonb, M.W., Kimb, W.B., DeLucac, P.P.,
Leea, K.C., 2003. Monitoring of peptide acylation inside degrading PLGA
microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry. J.
Control. Release., 92, 291-299.

.

Duan, Y., Sun, X., Gong, T., Wang, Q., Zhang, Z., 2006. Preparation of DHAQloaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release
behaviors in vitro/in vivo. J. Mater. Sci. Mater. Med., 17, 509-516.

28

Huang, X., Brazel, C.S., 2001. On the importance and mechanisms of burst
release in matrix-controlled drug delivery systems. J. Control. Release., 73, 121136.

Huang, YY., Chung, T.W., Tzeng, T.W., 1999. A method using biodegradable
polylactides/polyethylene glycol for drug release with reduced initial burst. Int. J.
Pharm., 182, 93-100.

Kosmidis, K., Rinaki, E., Argyrakis, P., Macheras, P., 2003. Analysis of Case II
drug transport with radial and axial release from cylinders. Int. J. Pharm., 254,
183-188.

Mu, L., Feng, S.S., 2002. A novel controlled release formulation for the
anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E
TPGS. J. Control. Release., 86, 33-48.

Park, T.G., 1994. Degradation of poly(dl-lactic acid) microspheres: effect of
molecular weight. J. Control. Release., 30,161-173.

Park, T.G., Cohen, S., Langer, R., 1992. Poly(L-lactic acid)/Pluronic blends:
characterization of phase separation behavior, degradation, and morphology and
use as protein-releasing matrices. Macromol., 25, 116-122.

29

Polakovic, M., Gorner, T., Gref, R., Dellacherie, E., 1999. Lidocaine loaded
biodegradable nanospheres II. Modelling of drug release. J. Control. Release., 60,
169-177.

Raman, C., Berkland, C., Kim, K., Pack, D.W., 2005. Modeling small-molecule
release from PLG microspheres: effects of polymer degradation and nonuniform
drug distribution. J. Control. Release., 103, 149-158.

Ravivarapu, H.B., Burton, K., DeLuca, P.P., 2000. Polymer and microsphere
blending to alter the release of a peptide from PLGA microspheres. Eur. J.
Pharm. Biopharm., 50, 263-270.

.

Ritger, P.L., Peppas, N.A., 1987. A simple equation for description of solute
release I. Fickian and non Fickian release from non-swellable devices in the form
of spheres, slabs, cylinders or discs. J. Control. Release., 5, 23-36.

Ritger, P.L., Peppas, N.A., 1987. A simple equation for description of solute
release II. Fickian and anamolous release from swellable devices. J. Control.
Release., 5, 37-42.

Rouzes, C., Leonard, M., Durand, A., Dellacherie, E., 2003. Influence of
polymeric surfactants on the properties of drug-loaded PLA nanospheres. Colloid
Surf. B: Biointerfaces, 32, 125-135.

30

Ruan, G., Feng, S.S., 2003. Preparation and characterization of poly(lactic acid)poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for
controlled release of paclitaxel. Biomater., 24, 5037-5044.

Siepmann, J., Elkharraz, K., Siepmann, F., Klose, D., 2005. How aoutocatalysis
accelrates drug release from PLGA-based microparticles: a quantitative treatment.
Biomacromol., 6, 2312-2319.

Woo, B.H., Jiang, G., Yeong, W., DeLuca, P.P., 2001. Preparation and
Characterization of a Composite PLGA and Poly(Acryloyl Hydroxyethyl Starch)
Microsphere System for Protein Delivery. Pharm. Res., 18, 1600-1606.

Zweers, M.L.T., Engbers, G.H.M., Grijpma, D.W., Feijen, J., 2004. In vitro
degradation of nanoparticles prepared from polymers based on DL-lactide,
glycolide and poly(ethylene oxide). J. Control. Release., 100, 347-356.

31

Figure 1
80

(a)

% Haloperidol Released

70
60
Induction amount

50

Batch 1
Batch 2

40
Batch 3
30

Initial burst

20

Induction
Period

10

Slow Release
Period

0
0

10

20

30

40

Time, days

100

% Haloperidol Released

90

(b)

80
70
60
50
40

PLA

30

PLGA 50:50, Batch 1

20

PLGA 50:50, Batch 2

10
0
0

10

20
Time, days

30

40

1

Figure 2
30

(a)

Haloperidol released, µg/ml

Drug content=2%

25
20

Drug content=1.7%

15
Drug content=0.66%

10
5
0
0

100

% Haloperidol Released

90

5

10

15

20
25
Time, days

30

35

40

(b)

80
70
60
50
40

Drug content=0.66%

30

Drug content=1.7%

20

Drug content=2%

10
0
0

5

10

15

20

25

30

35

40

Time, Days

2

Figure 3
80

(a)

PLA nanoparticles

% Haloperidol Released

70
60
50
40
30
Uncoated
Coated with gelatin
Coated with L101
Coated with chitosan

20
10
0
0

2

4

6

8

10

12

14

Time, days
80

(b)

Nanoparticles coated with chitosan

% Haloperidol Released

70
60
50
40
30
PLGA 50:50
20

PLA, Batch 1

10

PLA, Batch 2

0
0

5

10

15

20
Time, days

25

30

35

40

3

Figure 4
100

(a)

% Haloperidol Released

90

Diameter=220 nm
Diameter=450 nm

80

Diameter=1300 nm

70
60
50
40
30
20
10
0
0

5

10

15

20

25

30

35

Time, days
100

(b)

% Haloperidol Released

90

Diameter=220 nm

80

Diameter=450 nm

70

Diameter=1300 nm

R2 = 0.96
R2 = 0.96

60
50

R2 = 0.98

40
30
20
10
0
0

5

10

15

20

25

30

35

Time, days

100

(c)

% Haloperidol Released

90

Diameter=220 nm

80

Diameter=450 nm

70

Diameter=1300 nm

60
50
40
30
20
10
0
0

5

10

15

20

25

30

35

Time, days

4

Figure 5
100

(a)

% Haloperidol Released

90
80

Batch 1
Batch 2

70
60
50
40
30
20
10
0
0

2

4

6

8

10

Time, Days
100

% Haloperidol Released

90

(b)

80

PLGA 50:50, Batch 1
PLGA 50:50, Batch 2
PLA, Batch 1
PLA, Batch 2

70
60
50
40
30
20
10
0
0

10

20

30

40

50

Time, days

5

Table 1
Polymer

Drug

Mean Diameter

Diffusivity, D

(nm)

(cm2/s)

Reference

PLGA 50:50

Haloperidol

220

8*10-18

This paper

PLA

Haloperidol

220

5*10-19

This paper

PLA

Haloperidol

450

3*10-18

This paper

PLA

Haloperidol

1300

4*10-17

This paper

PLA

Lidocaine

225

5*10-16

Polakovic et al.,
1999

PLA

Lidocaine

200

7.7*10-17

Rouzes et al.,
2003

PLA

Tyrphostin AG1295

170

4*10-16

Chorny et al.,
2002

